Inhibrx Biosciences, Inc.

Inhibrx is a clinical-stage biopharmaceutical company that develops novel biologic therapeutic candidates using its proprietary modular protein engineering platforms. The company focuses on creating therapeutic candidates for challenging, validated targets. On May 29, 2024, Inhibrx, Inc., the Former Parent, spun off INBRX-101, an optimized, recombinant alpha-1 antitrypsin (AAT) augmentation therapy in a registrational trial for alpha-1 antitrypsin deficiency. This involved a distribution of 92% of Inhibrx's common stock to holders of the Former Parent's shares. On May 30, 2024, the Former Parent completed internal restructuring transactions, referred to as the Separation. Also on May 30, 2024, the Former Parent merged with Art Acquisition Sub, Inc., a subsidiary of Aventis Inc., which is a subsidiary of Sanofi S.A. Pursuant to this Merger, assets and liabilities primarily related to INBRX-101 were transferred to the Acquirer. Through the Separation, Inhibrx acquired the assets, liabilities, and corporate infrastructure for its ongoing programs, INBRX-106 and ozekibart (INBRX-109), and its discovery pipeline, along with close-out obligations for its terminated program, INBRX-105. Inhibrx now operates as a stand-alone, publicly traded company concentrating on ozekibart and INBRX-106, both of which are clinical-stage programs.